EffRx
601 Heritage Drive
Suite 208
Jupiter
Florida
33458
United States
Tel: 561-622-0321
Fax: 561-623-5509
Website: http://www.effrx.com/
Email: info@effrx.com
24 articles about EffRx
-
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland
10/21/2020
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi ® and Submits Market Authorization Application in Switzerland FREIENBACH, Switzerland--( BUSINESS WIRE )-- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a
-
EffRx Pharmaceuticals Signs Exclusive License Agreement with Pharmaxis for the Registration and Commercialization of Bronchitol® in Switzerland
6/13/2019
The product is inhaled as dry powder twice daily using a small handheld device and it is expected to be available on the Swiss market by 2021.
-
EffRx to Showcase Binosto® at the WCO-IOF-ESCEO 2019 in Paris
4/2/2019
EffRx Pharmaceuticals SA is proud to announce that it will participate in the 19th Edition of the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, taking place April 4-7, 2019 in Paris.
-
Binosto® Persistence and Efficacy Safety Data to be Presented at the ASBMR 2018 Congress in Montréal, Canada
9/26/2018
EffRx Pharmaceuticals SA is proud to announce that recent data from a standardized clinical database suggest an improved safety and tolerability profile of Binosto®
-
EffRx Binosto Data Presented At The ASBMR Congress In Denver
9/19/2017
-
EffRx: Osteoporosis Patients In Germany And Russia Get Access To Binosto
6/8/2017
-
Paolo Agnoluzzi Appointed CFO Of EffRx
6/1/2017
-
Lorenzo Bosisio Appointed CEO Of EffRx
10/11/2016
-
EffRx: First-In-Class Osteoporosis Treatment Binosto Launches In South Korea
1/7/2016
-
EffRx Announces Successful Label Variations Granted To Binosto In Europe
12/22/2015
-
New Partnership In Russia And CIS Further Expands Footprint For EffRx Proprietary Technologies
1/13/2015
-
EffRx Receives U.S. Orphan Drug Designation For EX404 For Treatment Of Pediatric Polycystic Ovary Syndrome
6/10/2014
-
EffRx Signs Binosto® Distribution Agreements In Russia And Africa
5/28/2014
-
EffRx Signs Distribution Agreements For Binosto® In Italy, Spain And Portugal
2/4/2014
-
Ascendancy Healthcare Announces Distribution Partnership With EffRx
11/4/2013
-
EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome (PCOS) in Paediatric Populations
10/1/2013
-
EffRx Signs Distribution Agreement With Ahn-Gook Pharmaceuticals for Binosto® for Korea
6/3/2013
-
Mission Pharmacal Company and EffRx Bring New Osteoporosis Medication to the United States and Canada
4/18/2012
-
FDA Approves EffRx's BINOSTO®, First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
3/14/2012
-
EffRx Announces Issuance of US Patent Providing Further Protection to EX101, Effervescent Alendronate Weekly Dosing Form
7/11/2011